Abbott Laboratories (ABT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for April 25, 2025, to be held virtually at 9:00 a.m. Central Time.
Proxy materials and annual report are available online, with options for electronic or paper delivery.
Voting matters and shareholder proposals
Shareholders will vote on the election of 12 directors, ratification of Ernst & Young LLP as auditors, and an advisory vote on executive compensation (Say on Pay).
Board recommends voting FOR all director nominees and FOR both auditor ratification and Say on Pay.
Board of directors and corporate governance
Twelve director nominees are listed for election, including R.J. Alpern, C. Babineaux-Fontenot, S.E. Blount, R.B. Ford, P. Gonzalez, M.A. Kumbier, D.W. McDew, N. McKinstry, M.G. O'Grady, M.F. Roman, D.J. Starks, and J.G. Stratton.
Latest events from Abbott Laboratories
- Q2 sales up 4% to $10.4B, driven by double-digit Medical Devices growth and raised guidance.ABT
Q2 20243 Feb 2026 - 2026 guidance targets 10% EPS growth and 7% organic sales growth, led by innovation and expansion.ABT
Q4 202522 Jan 2026 - Q3 sales up 4.9% to $10.6B, Medical Devices led growth, and adjusted EPS guidance increased.ABT
Q3 202419 Jan 2026 - Q4 organic sales up 10.1% and double-digit EPS growth, with strong 2025 outlook.ABT
Q4 20249 Jan 2026 - Q1 2025 saw strong sales and EPS growth, led by Medical Devices and Nutrition.ABT
Q1 20256 Jan 2026 - Board recommends approval of all proxy items, citing strong returns and ESG progress.ABT
Proxy Filing1 Dec 2025 - $21B deal creates a global cancer diagnostics leader, closing expected Q2 2026.ABT
M&A Announcement20 Nov 2025 - Q2 2025 sales up 7.4% to $11.1B, with strong EPS growth and Medical Devices leading.ABT
Q2 202513 Nov 2025 - Q3 sales up 6.9% to $11.4B, led by Medical Devices; EPS and guidance remain strong.ABT
Q3 202529 Oct 2025